

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A process to minimise loss of one or more of the components of a formulation through adhesion to equipment surfaces, which comprises addition of two or more of the components to a container in a stepwise manner.
2. (Currently Amended) A process for adding components to a multicomponent pharmaceutical formulation for inhalation comprising a ~~step-wise~~ stepwise addition of the components to a container in order to minimize or ~~iradicate~~ eradicate losses due to adhesion of component to the container surface.
3. (Currently Amended) A process according to claim 1[[ or 2]] in which the component of largest mass is added first.
4. (Currently Amended) A process according to claim 2[[ or 3]] in which the formulation components are active drug substances.
5. (Currently Amended) A process according to ~~any one of claims 2 to 4~~ claim 2 in which the formulation is for a pressurized metered dose inhaler.
6. (Currently Amended) A process according to claim 4[[ or 5]] in which the active drug substances are budesonide and formoterol, a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt.
7. (Currently Amended) A process according to ~~any one of claims 4 to 6~~ claim 4 in which the active drug substances are budesonide and formoterol fumarate dihydrate.

8. (Original) A process according to claim 7 in which the molar ratio of the budesonide to the formoterol fumarate dihydrate is from 2500:1 to 1:1.

9. (Currently Amended) A pharmaceutical formulation prepared according to the process defined in ~~any one of claims 2 to 8~~ claim 2.

10. (Currently Amended) A formulation according to claim 9 ~~which~~, wherein the formulation is in the form of a suspension.

11. (Original) A formulation according to claim 10 in which the drugs are suspended in one or more HFA propellants.

12. (Original) A formulation according to claim 11 in which the HFA propellants are HFA 134a or HFA 227 or a mixture thereof.

13. (Currently Amended) ~~Use of a formulation according to any one of claims 9 to 12~~ A method for the treatment or prophylaxis of asthma or COPD, comprising administering a formulation according to claim 9.

14. (Currently Amended) A method of treating asthma or COPD which ~~comprised~~ comprises administering to a patient in need of such treatment a formulation according to ~~any one of claims 9 to 12~~ claim 9.

15. (New) A process according to claim 2 in which the component of largest mass is added first.

16. (New) A process according to claim 1 in which the formulation components are active drug substances.